2.90
-0.11 (-3.65%)
AIStockmoo 评分
| 价值 30% | -1.4 |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 负债低。盈利能力弱。短期流动性偏紧。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -4.6 |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价接近均线。上涨日成交量较大。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 持仓情绪 参考 | NA |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 2.7 |
| 机构在最新13F申报中净+2.54%的股份:8家增持,5家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-88.5%,回补天数3.1天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利有升有降。近年曾亏损。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短期动能下降。 参考 | |
| 股价处于支撑位与阻力位之间。支撑与阻力水平趋升。 参考 | |
| 最终评分 | -1.48 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Pharmaceutical Retailers (US) | 混合的 | 混合的 |
| Pharmaceutical Retailers (全球的) | 混合的 | 混合的 | |
| 股票 | Scienture Holdings, Inc. | 混合的 | - |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| SCNX | - | - | - | 0.080 | -1.5 |
| WBA | 10 B | 4.34% | - | 1.44 | -2.0 |
| PETS | 19 M | - | - | 1.18 | -3.9 |
| RDGT | 853 K | - | - | 0.020 | -2.2 |
| MEDS | - | - | - | - | -2.1 |
| HITI | 199 M | - | - | 2.95 | -1.7 |
|
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders. |
|
| 部门 | Healthcare |
| 行业 | Pharmaceutical Retailers |
| 投资方式 | Small Value |
| 内部持股比例 | 32.59% |
| 机构持股比例 | 1.35% |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 6.24%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 8 | 41,998 |
| 减持 | 5 | 7,231 |
| 新建仓 | 2 | 15,999 |
| 清仓 | 1 | 5 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 117,350 | 3.1 |
| 15 Oct 2026 | 105,863 | 1.0 |
| 30 Sep 2026 | 1,304,235 | 1.0 |
| 15 Sep 2026 | 1,249,889 | 1.2 |
| 31 Aug 2026 | 1,022,272 | 2.6 |
| 14 Aug 2026 | 1,607,698 | 1.0 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 22 Oct 2026 | Yahoo Finance |
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™ Two FDA-Approved Commercial Products Position Company for Continued Sequential Revenue Growth High Gross Margins and… |
| 13 Oct 2026 | Yahoo Finance |
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial… |
| 13 Oct 2026 | Yahoo Finance |
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings Inc. (NASDAQ:SCNX) on Tuesday reported preliminary third-quarter revenue of approximately $1.22 million, up 256% from $344,000 in the previous quarter. The pharmaceutical company’s revenue growth reflected rising sales of its blood pressure medication, Arbli, and initial… |
| 02 Oct 2026 | Yahoo Finance |
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Major Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially Arbli™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually COMMACK, NY, Oct. 02, 2026 (GLOBE… |
| 02 Oct 2026 | Yahoo Finance |
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Scienture Holdings Inc. (NASDAQ:SCNX) on Friday announced that three leading U.S. pediatric academic medical centers added its proprietary hypertension medication to their formularies. These specialized hospitals, which focus on treating children with severe and chronic medical conditions, now… |
| 30 Sep 2026 | Yahoo Finance |
Scienture Holdings, Inc. Announces Reverse Stock Split
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization… |
| 22 Sep 2026 | Yahoo Finance |
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million… |
| 09 Sep 2026 | Yahoo Finance |
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli™ and the Commercial Launch of REZENOPY™ COMMACK, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on… |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 19 Jul 2024 | 08 Jul 2024 | 24 Jul 2024 | 1.5 现金 |
| 25 Mar 2024 | 28 Feb 2024 | 22 Mar 2024 | 8 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2024 | 9.50 | 2 | 157.03 |
技术形态 中期
AI 技术分析
投资组合